Karyopharm Therapeutics Inc.
KPTI · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $82,379 | $98,839 | $278,361 | $482,900 |
| - Cash | $62,476 | $52,231 | $135,188 | $190,459 |
| + Debt | $194,524 | $177,016 | $179,074 | $180,578 |
| Enterprise Value | $214,427 | $223,624 | $322,247 | $473,019 |
| Revenue | $145,237 | $146,033 | $157,074 | $209,819 |
| % Growth | -0.5% | -7% | -25.1% | – |
| Gross Profit | $139,230 | $141,091 | $151,861 | $206,417 |
| % Margin | 95.9% | 96.6% | 96.7% | 98.4% |
| EBITDA | -$38,603 | -$118,423 | -$139,305 | -$96,985 |
| % Margin | -26.6% | -81.1% | -88.7% | -46.2% |
| Net Income | -$76,422 | -$143,099 | -$165,291 | -$124,088 |
| % Margin | -52.6% | -98% | -105.2% | -59.1% |
| EPS Diluted | -9.41 | -18.79 | -30.28 | -24.75 |
| % Growth | 49.9% | 37.9% | -22.3% | – |
| Operating Cash Flow | -$127,486 | -$92,723 | -$149,554 | -$107,116 |
| Capital Expenditures | -$142 | $0 | -$118 | -$5,712 |
| Free Cash Flow | -$127,628 | -$92,723 | -$149,672 | -$112,828 |